Kodu・Aktsiate loetelu・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Avatud

SektorTervishoid

49.74 9.61

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

44.21

Max

48.35

Põhinäitajad
By Trading Economics
Sissetulek	2.8M -13M
Müük	-15M 151M
Aktsiakasum	0.07
Kasumimarginaal	-8.93
Töötajad	1,178
EBITDA	19M -937K

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	-5.7% downside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. nov 2026

Turustatistika
By TradingEconomics
Turukapital	3.2B 6B
Eelmine avamishind	40.13
Eelmine sulgemishind	49.74

Uudiste sentiment

By Acuity

100%

329 / 340 Pingereas Healthcare

10X Genomics Inc (Class A) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. aug 2026, 23:02 UTC

News

10X Genomics reported a net loss of $17.9 million for Q2, with shares trading lower in after-market hours amid concerns over an operating loss.

5. aug 2026, 19:26 UTC

Correlated Moves

News

10X Genomics Inc shares are lower amid broader market declines. The company reported $150.8 million in revenue last quarter, reflecting a year-on-year decline.

3. aug 2026, 19:36 UTC

Correlated Moves

Social Media

10X Genomics Inc reached a new 52-week high, reflecting strong market activity and positive sentiment in the genomics sector. Shares are higher since Friday's close.

31. juuli 2026, 19:36 UTC

Correlated Moves

Social Media

10X Genomics shares are lower today, continuing a decline since Thursday's close. The Russell 2000 Index also reflects broader market weakness.

30. juuli 2026, 17:06 UTC

Correlated Moves

10X Genomics Inc is higher today, supported by broader market trends and a significant rise since Wednesday's close. The stock peaked intraday with notable gains.

29. juuli 2026, 19:27 UTC

Macro Event

News

10X Genomics Inc announced a collaboration with Lausanne University Hospital to enhance cancer diagnostics. Shares are higher since Tuesday's close, reflecting positive sentiment.

28. juuli 2026, 23:11 UTC

10X Genomics Inc. is trading higher in after-market hours, maintaining a position near its one-month range's upper end. No specific news was identified for the move.

27. juuli 2026, 18:36 UTC

10X Genomics Inc shares are lower today, with no specific news identified. The stock remains near the upper end of its one-month range.

24. juuli 2026, 16:26 UTC

10X Genomics Inc shares declined during Friday's session, hitting a session low before a slight recovery. The stock remains above its 20-day moving average.

23. juuli 2026, 23:26 UTC

Correlated Moves

10X Genomics Inc shares declined in after-market trading, mirroring a broader market trend. The stock remains near the upper end of its one-month range.

22. juuli 2026, 19:51 UTC

Correlated Moves

10X Genomics Inc reports a first-quarter net loss of -$34 million, with revenue falling to $47 million, as shares trade lower amid broader market declines.

21. juuli 2026, 19:53 UTC

Correlated Moves

Positive investor sentiment drives 10X Genomics Inc higher amid a broader market recovery, reflecting gains since Monday's close and aligning with small-cap stock interest.

20. juuli 2026, 19:16 UTC

News

Correlated Moves

10X Genomics Inc. shares are lower as a report cites only 1.1% annual sales growth and ineffective growth strategies amid a declining Life Sciences Tools sector.

Võrdlus sarnastega

Hinnamuutus

10X Genomics Inc (Class A) Prognoos

Hinnasiht

By TipRanks

-5.7% langus

12 kuu keskmine prognoos

Keskmine 43 USD -5.7%

Kõrge 53 USD

Madal 23 USD

Põhineb 13 Wall Streeti analüütiku instrumendi 10X Genomics Inc (Class A) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi 10X Genomics Inc (Class A) aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.